By Adriano Marchese
LifeMD on Thursday said it will integrate with Eli Lilly's online pharmacy and healthcare platform to offer access to Lilly's prescription obesity treatment Zepbound in single-dose vials.
LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.
Zepbound is available for on-label self-pay patients in vials with dosages between 2.5 milligrams and 10 milligrams through LillyDirect's self-pay pharmacy channel.
Recently, Lilly reduced the price of some offerings of its 2.5 and 5 milligram vials.
"This new integration complements our insurance-sponsored pharmacy programs, where we continue to see rising approval rates for branded GLP-1 therapies like Zepbound," LifeMD Chairman and Chief Executive Justin Schreiber said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 06, 2025 08:51 ET (13:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。